Tech Company Financing Transactions
CorriXR Therapeutics Funding Round
Private investors participated in a $1 million capital raise for CorriXR Therapeutics. The round closed on 8/19/2025.
Transaction Overview
Company Name
Announced On
8/19/2025
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding will be instrumental in advancing CorriXR's lead program aimed at developing new treatments for solid tumors, with particular focus on head and neck, and lung cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
550 S. College Avenue 107
Newark, DE 19713
USA
Newark, DE 19713
USA
Phone
Undisclosed
Website
Email Address
Overview
CorriXR Therapeutics is an oncology-focused biotherapeutics development company enabled by a novel IP-protected in vivo gene editing therapeutic platform technology. We advance the science of gene editing by capitalizing on cutting-edge platform technology, having a strong team, and showcasing the ability to build ventures that address key areas with significant therapeutic gaps. Our team emphasizes equity, bringing our latest discoveries to diverse communities who are often excluded from clinical trials and treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Kmiec
Browse more venture capital transactions:
Prev: 8/19/2025: ChemFinity Technologies venture capital transaction
Next: 8/19/2025: Keychain venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs